Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 15/20 | 0.70 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | MMP1 | P03956 | 1/20 | 0.45 |
| ▸ | MMP3 | P08254 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1062410 | 1.00 | CCR2 (0.70) | CCR2RAB9ANPC1MMP1MMP3 | |
| SCHEMBL12061252 | 0.83 | CCR2 (0.97) | CCR2RAB9ANPC1 | |
| SCHEMBL242474 | 0.82 | CCR2 (1.00) | CCR2RAB9ANPC1 | |
| SCHEMBL13006180 | 0.82 | CCR2 (1.00) | CCR2RAB9ANPC1 | |
| SCHEMBL12061277 | 0.82 | CCR2 (1.00) | CCR2RAB9ANPC1 | |
| SCHEMBL12061309 | 0.78 | CCR2 (0.82) | CCR2RAB9A | |
| SCHEMBL1081727 | 0.78 | CCR2 (0.92) | CCR2RAB9ANPC1 | |
| SCHEMBL1080106 | 0.77 | CCR2 (0.41) | CCR2 | |
| SCHEMBL1062408 | 0.77 | CCR2 (0.41) | CCR2 | |
| SCHEMBL12061265 | 0.76 | CCR2 (0.55) | CCR2RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1896036-B1 | ANTI-INFLAMMATORY AGENTS | CAMBRIDGE ENTPR LTD (GB) | 2013-01-23 | — | — | EP | disclosed |
| US-8076323-B2 | Anti-inflammatory agents | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2011-12-13 | — | — | US | disclosed |
| US-20110003792-A1 | ANTI-INFLAMMATORY AGENTS | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2011-01-06 | — | — | US | disclosed |
| US-7803794-B2 | Anti-inflammatory agents | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2010-09-28 | — | — | US | disclosed |
| US-20100016286-A1 | Anti-Inflammatory Agents | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2010-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016286-A1 | Anti-Inflammatory Agents | TNF, LTC4S, IL6 | CCR2 54/4885RAB9A 3745/4885NPC1 3112/4885 |
| US-20110003792-A1 | ANTI-INFLAMMATORY AGENTS | TNF, LTC4S, PTGS1 | CCR2 45/4885RAB9A 4003/4885NPC1 2704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.